0 XP   0   0   0

Alkem Laboratories Ltd
Buy, Hold or Sell?

Should you buy, hold or sell Alkem Laboratories Ltd?

I guess you are interested in Alkem Laboratories Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Alkem Laboratories Ltd

Let's start. I'm going to help you getting a better view of Alkem Laboratories Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Alkem Laboratories Ltd even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Alkem Laboratories Ltd is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Alkem Laboratories Ltd. The closing price on 2023-02-07 was INR3,066 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Alkem Laboratories Ltd Daily Candlestick Chart
Alkem Laboratories Ltd Daily Candlestick Chart
Summary









1. Valuation of Alkem Laboratories Ltd




Current price per share

INR3,065.50

2. Growth of Alkem Laboratories Ltd




Is Alkem Laboratories Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$892.5m$152.6m14.6%

How much money is Alkem Laboratories Ltd making?

Current yearPrevious yearGrowGrow %
Making money$199.1m$191.7m$7.3m3.7%
Net Profit Margin15.5%17.9%--

How much money comes from the company's main activities?

3. Financial Health of Alkem Laboratories Ltd




Comparing to competitors in the Pharmaceuticals industry




  Industry Rankings (Pharmaceuticals)  


Richest
#14 / 52

Most Revenue
#13 / 52


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Alkem Laboratories Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alkem Laboratories Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 15.5% means that ₹0.15 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alkem Laboratories Ltd:

  • The MRQ is 15.5%. The company is making a huge profit. +2
  • The TTM is 15.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.5%TTM15.5%0.0%
TTM15.5%YOY17.9%-2.4%
TTM15.5%5Y13.4%+2.1%
5Y13.4%10Y13.5%-0.1%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ15.5%3.3%+12.2%
TTM15.5%6.9%+8.6%
YOY17.9%9.9%+8.0%
5Y13.4%6.3%+7.1%
10Y13.5%6.7%+6.8%
1.1.2. Return on Assets

Shows how efficient Alkem Laboratories Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • 11.7% Return on Assets means that Alkem Laboratories Ltd generated ₹0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alkem Laboratories Ltd:

  • The MRQ is 11.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 11.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ11.7%TTM11.7%0.0%
TTM11.7%YOY13.8%-2.1%
TTM11.7%5Y10.9%+0.8%
5Y10.9%10Y11.0%-0.1%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7%0.8%+10.9%
TTM11.7%1.3%+10.4%
YOY13.8%1.5%+12.3%
5Y10.9%1.4%+9.5%
10Y11.0%1.4%+9.6%
1.1.3. Return on Equity

Shows how efficient Alkem Laboratories Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • 19.1% Return on Equity means Alkem Laboratories Ltd generated ₹0.19 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alkem Laboratories Ltd:

  • The MRQ is 19.1%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 19.1%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ19.1%TTM19.1%0.0%
TTM19.1%YOY21.5%-2.4%
TTM19.1%5Y17.2%+1.9%
5Y17.2%10Y17.3%-0.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ19.1%1.5%+17.6%
TTM19.1%2.0%+17.1%
YOY21.5%3.0%+18.5%
5Y17.2%2.1%+15.1%
10Y17.3%2.0%+15.3%

1.2. Operating Efficiency of Alkem Laboratories Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alkem Laboratories Ltd is operating .

  • Measures how much profit Alkem Laboratories Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alkem Laboratories Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y8.4%-8.4%
5Y8.4%10Y10.6%-2.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ--5.6%+5.6%
TTM-0.5%-0.5%
YOY-6.2%-6.2%
5Y8.4%5.1%+3.3%
10Y10.6%5.2%+5.4%
1.2.2. Operating Ratio

Measures how efficient Alkem Laboratories Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are ₹1.22 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 1.225. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.225. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.225TTM1.2250.000
TTM1.225YOY1.217+0.008
TTM1.2255Y1.242-0.017
5Y1.24210Y1.269-0.028
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2251.342-0.117
TTM1.2251.276-0.051
YOY1.2171.169+0.048
5Y1.2421.149+0.093
10Y1.2691.178+0.091

1.3. Liquidity of Alkem Laboratories Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alkem Laboratories Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 1.76 means the company has ₹1.76 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 1.755. The company is able to pay all its short-term debts. +1
  • The TTM is 1.755. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.755TTM1.7550.000
TTM1.755YOY1.923-0.167
TTM1.7555Y1.792-0.036
5Y1.79210Y1.643+0.148
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7552.205-0.450
TTM1.7552.010-0.255
YOY1.9232.125-0.202
5Y1.7921.812-0.020
10Y1.6431.786-0.143
1.3.2. Quick Ratio

Measures if Alkem Laboratories Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.89 means the company can pay off ₹0.89 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 0.891. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.891. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.891TTM0.8910.000
TTM0.891YOY1.371-0.480
TTM0.8915Y1.063-0.172
5Y1.06310Y0.920+0.143
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8911.118-0.227
TTM0.8911.152-0.261
YOY1.3711.091+0.280
5Y1.0631.007+0.056
10Y0.9200.869+0.051

1.4. Solvency of Alkem Laboratories Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alkem Laboratories Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alkem Laboratories Ltd to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.39 means that Alkem Laboratories Ltd assets are financed with 38.6% credit (debt) and the remaining percentage (100% - 38.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 0.386. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.386. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.386TTM0.3860.000
TTM0.386YOY0.360+0.026
TTM0.3865Y0.366+0.020
5Y0.36610Y0.367-0.001
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3860.381+0.005
TTM0.3860.379+0.007
YOY0.3600.417-0.057
5Y0.3660.398-0.032
10Y0.3670.399-0.032
1.4.2. Debt to Equity Ratio

Measures if Alkem Laboratories Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 62.9% means that company has ₹0.63 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 0.629. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.629. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.629TTM0.6290.000
TTM0.629YOY0.562+0.067
TTM0.6295Y0.578+0.051
5Y0.57810Y0.585-0.008
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6290.586+0.043
TTM0.6290.598+0.031
YOY0.5620.598-0.036
5Y0.5780.671-0.093
10Y0.5850.664-0.079

2. Market Valuation of Alkem Laboratories Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Alkem Laboratories Ltd generates.

  • Above 15 is considered overpriced but always compare Alkem Laboratories Ltd to the Pharmaceuticals industry mean.
  • A PE ratio of 26.28 means the investor is paying ₹26.28 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alkem Laboratories Ltd:

  • The EOD is 22.273. Very good. +2
  • The MRQ is 26.281. Very good. +2
  • The TTM is 26.281. Very good. +2
Trends
Current periodCompared to+/- 
EOD22.273MRQ26.281-4.008
MRQ26.281TTM26.2810.000
TTM26.281YOY20.912+5.369
TTM26.2815Y27.381-1.100
5Y27.38110Y18.498+8.882
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD22.27340.785-18.512
MRQ26.28151.661-25.380
TTM26.28151.419-25.138
YOY20.91264.495-43.583
5Y27.38156.903-29.522
10Y18.49861.712-43.214
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Alkem Laboratories Ltd.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Alkem Laboratories Ltd:

  • The MRQ is 25.313. Seems overpriced? -1
  • The TTM is 25.313. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ25.313TTM25.3130.000
TTM25.313YOY14.870+10.443
TTM25.3135Y26.534-1.221
5Y26.53410Y26.5340.000
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ25.3130.015+25.298
TTM25.3130.036+25.277
YOY14.8700.327+14.543
5Y26.5340.144+26.390
10Y26.5340.144+26.390

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alkem Laboratories Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 5.01 means the investor is paying ₹5.01 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Alkem Laboratories Ltd:

  • The EOD is 4.243. Neutral. Compare to industry.
  • The MRQ is 5.007. Seems overpriced? -1
  • The TTM is 5.007. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD4.243MRQ5.007-0.764
MRQ5.007TTM5.0070.000
TTM5.007YOY4.493+0.513
TTM5.0075Y4.546+0.461
5Y4.54610Y3.182+1.364
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD4.2432.248+1.995
MRQ5.0072.690+2.317
TTM5.0073.050+1.957
YOY4.4933.185+1.308
5Y4.5462.899+1.647
10Y3.1822.711+0.471
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Alkem Laboratories Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--105.480105.4800%101.707+4%69.757+51%120.407-12%
Book Value Growth--1.1711.1710%1.197-2%1.142+3%1.164+1%
Book Value Per Share--722.444722.4440%616.964+17%543.276+33%343.338+110%
Book Value Per Share Growth--1.1711.1710%1.197-2%1.142+3%1.142+3%
Current Ratio--1.7551.7550%1.923-9%1.792-2%1.643+7%
Debt To Asset Ratio--0.3860.3860%0.360+7%0.366+6%0.367+5%
Debt To Equity Ratio--0.6290.6290%0.562+12%0.578+9%0.585+7%
Dividend Per Share--35.28735.2870%28.000+26%24.656+43%21.547+64%
Dividend Per Share Growth--1.2601.2600%0.933+35%1.539-18%1.539-18%
Eps--137.634137.6340%132.566+4%96.168+43%61.716+123%
Eps Growth--1.0381.0380%1.406-26%1.168-11%1.168-11%
Free Cash Flow Per Share--64.57964.5790%89.490-28%31.862+103%24.131+168%
Free Cash Flow Per Share Growth--0.7220.7220%4.820-85%1.740-59%1.740-59%
Free Cash Flow To Equity Per Share--96.32596.3250%66.762+44%30.065+220%20.711+365%
Free Cash Flow To Equity Per Share Growth--1.4431.4430%2.651-46%2.191-34%2.191-34%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2028.163--------
Intrinsic Value_10Y_min--1693.092--------
Intrinsic Value_1Y_max--94.685--------
Intrinsic Value_1Y_min--92.005--------
Intrinsic Value_3Y_max--367.219--------
Intrinsic Value_3Y_min--345.335--------
Intrinsic Value_5Y_max--739.493--------
Intrinsic Value_5Y_min--672.229--------
Net Profit Margin--0.1550.1550%0.179-13%0.134+15%0.135+15%
Operating Margin----0%-0%0.084-100%0.106-100%
Operating Ratio--1.2251.2250%1.217+1%1.242-1%1.269-4%
Pb Ratio4.243-18%5.0075.0070%4.493+11%4.546+10%3.182+57%
Pe Ratio22.273-18%26.28126.2810%20.912+26%27.381-4%18.498+42%
Peg Ratio--25.31325.3130%14.870+70%26.534-5%26.534-5%
Price Per Share3065.500-18%3617.1003617.1000%2772.200+30%2489.390+45%1780.044+103%
Price To Total Gains Ratio21.777-18%25.69625.6960%21.373+20%28.335-9%24.581+5%
Profit Growth--1.0381.0380%1.406-26%1.168-11%1.229-16%
Quick Ratio--0.8910.8910%1.371-35%1.063-16%0.920-3%
Return On Assets--0.1170.1170%0.138-15%0.109+8%0.110+7%
Return On Equity--0.1910.1910%0.215-11%0.172+11%0.173+10%
Revenue Growth--1.2001.2000%1.062+13%1.128+6%1.168+3%
Total Gains Per Share--140.767140.7670%129.707+9%94.413+49%141.954-1%
Total Gains Per Share Growth--1.0851.0850%1.436-24%1.078+1%1.078+1%
Usd Book Value--1045185900.0001045185900.0000%892584330.000+17%785977522.000+33%622505473.333+68%
Usd Book Value Change Per Share--1.2761.2760%1.231+4%0.844+51%1.457-12%
Usd Book Value Per Share--8.7428.7420%7.465+17%6.574+33%4.154+110%
Usd Dividend Per Share--0.4270.4270%0.339+26%0.298+43%0.261+64%
Usd Eps--1.6651.6650%1.604+4%1.164+43%0.747+123%
Usd Free Cash Flow--93428940.00093428940.0000%129468790.000-28%46096160.000+103%25608977.778+265%
Usd Free Cash Flow Per Share--0.7810.7810%1.083-28%0.386+103%0.292+168%
Usd Free Cash Flow To Equity Per Share--1.1661.1660%0.808+44%0.364+220%0.251+365%
Usd Price Per Share37.093-18%43.76743.7670%33.544+30%30.122+45%21.539+103%
Usd Profit--199120020.000199120020.0000%191787420.000+4%139129672.000+43%110374990.000+80%
Usd Revenue--1286736990.0001286736990.0000%1072666210.000+20%1007492706.000+28%798529685.556+61%
Usd Total Gains Per Share--1.7031.7030%1.569+9%1.142+49%1.718-1%
 EOD+3 -2MRQTTM+0 -0YOY+19 -225Y+29 -1310Y+26 -16

3.2. Fundamental Score

Let's check the fundamental score of Alkem Laboratories Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1522.273
Price to Book Ratio (EOD)Between0-14.243
Net Profit Margin (MRQ)Greater than00.155
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.891
Current Ratio (MRQ)Greater than11.755
Debt to Asset Ratio (MRQ)Less than10.386
Debt to Equity Ratio (MRQ)Less than10.629
Return on Equity (MRQ)Greater than0.150.191
Return on Assets (MRQ)Greater than0.050.117
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Alkem Laboratories Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.505
Ma 20Greater thanMa 503,038.653
Ma 50Greater thanMa 1003,055.333
Ma 100Greater thanMa 2003,118.614
OpenGreater thanClose3,084.950
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets140,691,900
Total Liabilities54,312,900
Total Stockholder Equity86,379,000
 As reported
Total Liabilities 54,312,900
Total Stockholder Equity+ 86,379,000
Total Assets = 140,691,900

Assets

Total Assets140,691,900
Total Current Assets84,354,300
Long-term Assets84,354,300
Total Current Assets
Cash And Cash Equivalents 2,291,800
Short-term Investments 10,808,500
Net Receivables 18,879,700
Inventory 30,630,100
Other Current Assets 14,292,600
Total Current Assets  (as reported)84,354,300
Total Current Assets  (calculated)76,902,700
+/- 7,451,600
Long-term Assets
Property Plant Equipment 27,659,300
Goodwill 4,030,900
Intangible Assets 721,900
Other Assets 13,396,500
Long-term Assets  (as reported)56,337,600
Long-term Assets  (calculated)45,808,600
+/- 10,529,000

Liabilities & Shareholders' Equity

Total Current Liabilities48,053,400
Long-term Liabilities4,165,200
Total Stockholder Equity86,379,000
Total Current Liabilities
Short-term Debt 25,707,400
Short Long Term Debt 25,707,400
Accounts payable 11,733,800
Other Current Liabilities 1,503,200
Total Current Liabilities  (as reported)48,053,400
Total Current Liabilities  (calculated)64,651,800
+/- 16,598,400
Long-term Liabilities
Long term Debt Total 758,500
Long term Debt 93,800
Capital Lease Obligations 880,700
Long-term Liabilities Other 79,200
Long-term Liabilities  (as reported)4,165,200
Long-term Liabilities  (calculated)1,812,200
+/- 2,353,000
Total Stockholder Equity
Common Stock239,100
Retained Earnings 85,816,600
Other Stockholders Equity 317,300
Total Stockholder Equity (as reported)86,379,000
Total Stockholder Equity (calculated)86,373,000
+/- 6,000
Other
Capital Stock239,100
Cash And Equivalents30,000
Cash and Short Term Investments 13,130,300
Common Stock Shares Outstanding 119,565
Liabilities and Stockholders Equity 140,691,900
Net Debt 23,479,400
Net Invested Capital 112,180,200
Net Working Capital 36,300,900



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
43,165,900
52,957,600
55,346,600
65,680,500
76,656,300
82,081,900
99,433,300
115,192,600
140,691,900
140,691,900115,192,60099,433,30082,081,90076,656,30065,680,50055,346,60052,957,60043,165,900
   > Total Current Assets 
16,021,500
23,380,500
27,687,000
29,171,400
40,132,200
42,161,300
54,960,300
69,288,200
84,354,300
84,354,30069,288,20054,960,30042,161,30040,132,20029,171,40027,687,00023,380,50016,021,500
       Cash And Cash Equivalents 
2,062,900
7,907,600
38,400
618,100
138,300
1,508,800
212,900
1,646,800
2,291,800
2,291,8001,646,800212,9001,508,800138,300618,10038,4007,907,6002,062,900
       Short-term Investments 
343,440
610,500
2,741,800
2,779,700
6,578,100
6,403,500
2,843,500
15,794,800
10,808,500
10,808,50015,794,8002,843,5006,403,5006,578,1002,779,7002,741,800610,500343,440
       Net Receivables 
4,138,900
5,811,400
5,675,100
8,752,300
12,751,600
14,087,300
19,109,500
16,072,100
18,879,700
18,879,70016,072,10019,109,50014,087,30012,751,6008,752,3005,675,1005,811,4004,138,900
       Inventory 
6,203,300
7,842,300
9,407,100
12,060,000
14,421,900
14,998,700
18,188,200
23,317,300
30,630,100
30,630,10023,317,30018,188,20014,998,70014,421,90012,060,0009,407,1007,842,3006,203,300
       Other Current Assets 
3,113,660
1,060,900
600
2,878,200
6,957,100
6,211,900
12,741,600
4,375,100
14,292,600
14,292,6004,375,10012,741,6006,211,9006,957,1002,878,2006001,060,9003,113,660
   > Long-term Assets 
0
0
0
36,673,300
37,504,400
39,920,600
44,473,000
45,904,400
56,337,600
56,337,60045,904,40044,473,00039,920,60037,504,40036,673,300000
       Property Plant Equipment 
9,796,700
10,833,400
12,034,500
16,937,100
22,542,700
25,985,800
27,741,400
27,064,300
27,659,300
27,659,30027,064,30027,741,40025,985,80022,542,70016,937,10012,034,50010,833,4009,796,700
       Goodwill 
1,903,400
3,535,400
3,746,400
3,658,800
3,664,400
3,805,600
3,984,500
3,953,900
4,030,900
4,030,9003,953,9003,984,5003,805,6003,664,4003,658,8003,746,4003,535,4001,903,400
       Long Term Investments 
11,062,900
7,325,700
3,187,800
5,365,400
0
0
0
0
0
000005,365,4003,187,8007,325,70011,062,900
       Intangible Assets 
0
481,500
438,700
367,100
438,600
442,600
983,900
844,400
721,900
721,900844,400983,900442,600438,600367,100438,700481,5000
       Long-term Assets Other 
0
0
0
172,900
189,400
100
0
564,000
200
200564,0000100189,400172,900000
> Total Liabilities 
17,372,400
22,110,600
18,427,000
21,004,100
28,018,600
27,688,500
37,826,600
41,425,300
54,312,900
54,312,90041,425,30037,826,60027,688,50028,018,60021,004,10018,427,00022,110,60017,372,400
   > Total Current Liabilities 
14,055,800
20,059,800
15,376,000
16,896,900
23,833,100
22,175,300
32,433,100
36,040,500
48,053,400
48,053,40036,040,50032,433,10022,175,30023,833,10016,896,90015,376,00020,059,80014,055,800
       Short-term Debt 
11,332,200
13,110,600
4,641,700
4,723,700
7,612,700
6,712,700
15,035,100
16,359,600
25,707,400
25,707,40016,359,60015,035,1006,712,7007,612,7004,723,7004,641,70013,110,60011,332,200
       Short Long Term Debt 
11,332,200
13,110,600
6,575,000
6,594,600
8,668,300
7,127,700
15,416,100
16,359,600
25,707,400
25,707,40016,359,60015,416,1007,127,7008,668,3006,594,6006,575,00013,110,60011,332,200
       Accounts payable 
3,057,300
4,659,300
5,804,800
7,413,700
9,607,100
9,622,500
9,540,500
10,694,100
11,733,800
11,733,80010,694,1009,540,5009,622,5009,607,1007,413,7005,804,8004,659,3003,057,300
       Other Current Liabilities 
451,200
638,100
1,167,600
1,260,500
1,471,200
1,382,100
2,021,100
1,193,400
1,503,200
1,503,2001,193,4002,021,1001,382,1001,471,2001,260,5001,167,600638,100451,200
   > Long-term Liabilities 
0
0
0
3,227,800
2,970,000
4,460,200
3,910,500
3,572,000
4,165,200
4,165,2003,572,0003,910,5004,460,2002,970,0003,227,800000
       Long term Debt Total 
0
0
1,234,600
1,815,600
1,307,300
2,313,000
1,592,400
976,400
758,500
758,500976,4001,592,4002,313,0001,307,3001,815,6001,234,60000
       Capital Lease Obligations 
0
0
0
0
63,300
63,200
1,134,700
278,700
880,700
880,700278,7001,134,70063,20063,3000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
88,300
79,200
79,20088,3000000000
> Total Stockholder Equity
25,793,500
29,990,500
36,919,600
44,676,400
48,637,700
54,393,400
61,606,700
73,767,300
86,379,000
86,379,00073,767,30061,606,70054,393,40048,637,70044,676,40036,919,60029,990,50025,793,500
   Common Stock
119,600
239,100
239,100
239,100
239,100
239,100
239,100
239,100
239,100
239,100239,100239,100239,100239,100239,100239,100239,100119,600
   Retained Earnings 
25,610,600
29,588,000
36,534,100
44,509,200
48,655,200
54,094,700
61,037,400
73,545,200
85,816,600
85,816,60073,545,20061,037,40054,094,70048,655,20044,509,20036,534,10029,588,00025,610,600
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
63,300
163,400
146,200
-71,900
-256,600
59,600
330,200
-28,200
317,300
317,300-28,200330,20059,600-256,600-71,900146,200163,40063,300



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue106,341,900
Cost of Revenue-42,638,200
Gross Profit63,703,70063,703,700
 
Operating Income (+$)
Gross Profit63,703,700
Operating Expense-87,588,700
Operating Income17,715,100-23,885,000
 
Operating Expense (+$)
Research Development-
Selling General Administrative42,402,700
Selling And Marketing Expenses-
Operating Expense87,588,70042,402,700
 
Net Interest Income (+$)
Interest Income671,600
Interest Expense-408,400
Net Interest Income703,100263,200
 
Pretax Income (+$)
Operating Income17,715,100
Net Interest Income703,100
Other Non-Operating Income Expenses-
Income Before Tax (EBT)18,442,80017,715,100
EBIT - interestExpense = -408,400
16,456,200
16,864,600
Interest Expense408,400
Earnings Before Interest and Taxes (ebit)-18,851,200
Earnings Before Interest and Taxes (ebitda)21,890,800
 
After tax Income (+$)
Income Before Tax18,442,800
Tax Provision-1,639,600
Net Income From Continuing Ops16,803,20016,803,200
Net Income16,456,200
Net Income Applicable To Common Shares16,456,200
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--703,100
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
33637L.KO
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 33637L.KO.

33637L.KO Daily Candlestick Chart
LOOMIS.ST
38 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LOOMIS.ST.

LOOMIS.ST Daily Candlestick Chart
KFAST-B.ST
38 minutes ago

I found you a Golden Cross on the daily chart of KFAST-B.ST.

KFAST-B.ST Daily Candlestick Chart
COALA.ST
40 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of COALA.ST.

COALA.ST Daily Candlestick Chart
CFISH.ST
40 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CFISH.ST.

CFISH.ST Daily Candlestick Chart
UIFS.LSE
51 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of UIFS.LSE.

UIFS.LSE Daily Candlestick Chart
RNF.F
55 minutes ago

I found you a RSI Bullish Hidden Divergence on the daily chart of RNF.F.

RNF.F Daily Candlestick Chart
IXX.F
56 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of IXX.F.

IXX.F Daily Candlestick Chart
4AP.F
57 minutes ago

I found you a MACD Bearish Hidden Divergence on the daily chart of 4AP.F.

4AP.F Daily Candlestick Chart
5IC.SG
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 5IC.SG.

5IC.SG Daily Candlestick Chart
INFOMEDIA.BSE
3 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of INFOMEDIA.BSE.

INFOMEDIA.BSE Daily Candlestick Chart
PNAX.TA
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PNAX.TA.

PNAX.TA Daily Candlestick Chart
SHI.VN
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SHI.VN.

SHI.VN Daily Candlestick Chart
HLC.VN
3 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of HLC.VN.

HLC.VN Daily Candlestick Chart
VPI.VN
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VPI.VN.

VPI.VN Daily Candlestick Chart
CIA.VN
3 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CIA.VN.

CIA.VN Daily Candlestick Chart
GKM.VN
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GKM.VN.

GKM.VN Daily Candlestick Chart
TDN.VN
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TDN.VN.

TDN.VN Daily Candlestick Chart
TC6.VN
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TC6.VN.

TC6.VN Daily Candlestick Chart
40N.SG
3 hours ago

I found you a MACD Bullish Reversal Divergence on the daily chart of 40N.SG.

40N.SG Daily Candlestick Chart
HOR.AU
4 hours ago

I found you a Golden Cross on the daily chart of HOR.AU.

HOR.AU Daily Candlestick Chart
IS3.AU
4 hours ago

I found you a RSI Bullish Reversal Divergence on the daily chart of IS3.AU.

IS3.AU Daily Candlestick Chart
CEI.PSE
4 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of CEI.PSE.

CEI.PSE Daily Candlestick Chart
COH.AU
4 hours ago

I found you a Golden Cross on the daily chart of COH.AU.

COH.AU Daily Candlestick Chart
CLV.AU
4 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CLV.AU.

CLV.AU Daily Candlestick Chart